Cell Therapy Types: The Complete 2026 Classification Map

Introduction: Why Cell Therapy Needs a Classification Map

Cell therapy is not a single treatment. It is a growing family of medical approaches that use living cells as the active therapeutic ingredient. These approaches range from bone marrow transplants that have been used for decades to genetically engineered immune cells that hunt down cancer. As the field diversifies, the same therapy can be described in several different ways depending on who is describing it and why.

A clinician may call a product “autologous.” A scientist may call it “a non-stem cell, unicellular therapy.” A regulator may classify it as a “351 product” or an “Advanced Therapy Medicinal Product.” An oncologist may simply call it “CAR-T.” All of these labels can be accurate at the same time, because cell therapies are classified along multiple overlapping axes: origin, biological cell type, scientific category, regulatory status, and clinical application.

Most existing explanations of cell therapy types cover only one of these lenses, usually the autologous versus allogeneic distinction or CAR-T therapy alone. That leaves patients, students, and professionals without a unified reference. This guide is designed to fill that gap by bridging accessible explanation with scientific and regulatory rigor. For a broader overview of where the field stands today, see this cell therapy review.

The article covers four main classification lenses:

1. Origin of cells (who the cells come from)
2. Biological source and type (what kind of cells they are)
3. Academic and regulatory categories (how researchers and governments define them)
4. The oncology adoptive-cell landscape (the fastest-moving segment in 2026)

Readers exploring cell therapy types for the first time can treat this map as a starting point before moving on to disease-specific or treatment-specific topics.

Classification by Cell Origin: Autologous, Allogeneic, Syngeneic, and Xenogeneic

Classification by cell origin is the most foundational and widely used framework in both clinical and consumer contexts. It answers a simple question: whose cells are being used? Current cell therapies in development fall primarily into two major categories, autologous and allogeneic, though two additional categories complete the picture.

Autologous Cell Therapy

Autologous therapies use cells taken from the patient’s own body. The cells are collected, processed or modified, and then returned to the same person. Because the cells are the patient’s own, the risk of immune rejection is low. The tradeoff is that each treatment is a custom, single-patient manufacturing process, which can be time-consuming and logistically complex.

Examples include all currently approved CAR-T therapies and the sickle cell gene therapies Casgevy and Lyfgenia.

Allogeneic Cell Therapy

Allogeneic therapies use cells from a donor. This approach opens the door to “off-the-shelf” products that can be manufactured in advance, stored, and given to many patients. The main challenges are immune compatibility, including the risk of rejection and graft-versus-host disease (GVHD), in which donor immune cells attack the recipient’s tissues.

The American Cancer Society notes that stem cell transplants are commonly divided into these same two types, autologous and allogeneic, named according to who donates the cells.

Syngeneic Cell Therapy

Syngeneic therapy uses cells from a genetically identical individual, most commonly an identical twin. It is a less common category used mainly in transplant medicine. Because the donor and recipient share the same genetic makeup, immune compatibility issues are minimal.

Xenogeneic Cell Therapy

Xenogeneic therapy involves non-human cells, such as cells derived from animals. Safety and compatibility issues, including immune reactions and the potential transmission of animal pathogens, currently limit its clinical use. It remains largely an area of research rather than routine practice.

Classification by Cell Source and Biological Type

Where origin describes who the cells come from, this lens describes what kind of cells they biologically are. This distinction matters because cell type shapes differentiation potential (what the cells can become), manufacturing complexity, and the range of clinical applications.

Stem Cells

Stem cells are broadly classified into three main types, each with distinct characteristics and capabilities for differentiation:

• Embryonic stem cells (ESCs): Derived from early-stage embryos, these cells are pluripotent, meaning they can develop into nearly any cell type in the body. Their use raises ethical considerations and regulatory restrictions in many jurisdictions.
• Induced pluripotent stem cells (iPSCs): Adult cells that have been reprogrammed in the laboratory to behave like embryonic stem cells. iPSCs offer pluripotent potential without the use of embryos and are increasingly explored as a renewable source for allogeneic products.
• Adult stem cells: Found in tissues throughout the body, these cells are typically more limited in what they can become. Two of the most clinically important types are:
  • Hematopoietic stem cells (HSCs): Located in the bone marrow, where they generate all blood and immune cell types.
  • Mesenchymal stem or stromal cells (MSCs): Found in sources such as umbilical cord blood, amniotic fluid, bone marrow, and adipose (fat) tissue. MSCs can generate osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells), and they are widely studied for their immune-modulating effects.

Non-Stem Immune and Somatic Cells

Many of the most visible cell therapies do not use stem cells at all. Instead, they use mature, specialized cells:

• T cells: The foundation of CAR-T and TIL therapies.
• Natural killer (NK) cells: Innate immune cells with built-in ability to kill abnormal cells.
• Dendritic cells: Antigen-presenting cells that train the immune system to recognize threats.
• Other somatic cells: Such as chondrocytes, keratinocytes, or fibroblasts used in tissue repair applications.

Academic and Scientific Classification Frameworks

Beyond origin and cell type, scientific literature uses a more rigorous classification layer that is rarely explained to general audiences. A widely cited review in the PMC database, Cell Therapy: Types, Regulation, and Clinical Benefits, organizes cell therapy along two additional axes.

Stem Cell-Based vs. Non-Stem Cell-Based Therapies

• Stem cell-based therapies rely on cells with self-renewal and differentiation capacity, such as HSC transplants or MSC products.
• Non-stem cell-based therapies use mature, differentiated cells, such as engineered T cells or dendritic cells.

Unicellular vs. Multicellular Therapies

• Unicellular therapies use a single, defined cell population, such as purified CAR-T cells.
• Multicellular therapies combine multiple cell types, sometimes alongside scaffolds or supporting tissue, as in some tissue-engineered products.

According to the same review, these categories differ in their immunophenotypic profiles (the surface markers that identify the cells), isolation techniques, mechanisms of action, and regulatory levels. This framework helps explain why two therapies that look similar on the surface can face very different scientific and regulatory challenges.

A separate academic review on cell-based therapy classifications notes that therapies can also be grouped by therapeutic indication, by autologous or allogeneic source, or most commonly by cell type, often mapped onto the European regulatory framework described below.

Regulatory Classification: How Governments Define Cell Therapy Categories

Scientific taxonomy has real-world consequences. How a product is classified by regulators determines its approval pathway, the level of oversight it receives, and the evidence required before it can reach patients. This lens is especially valuable for biotech professionals, investors, and informed patients evaluating claims about a given therapy. For a deeper look at how trial evidence factors into these evaluations, see why clinical studies matter in regenerative medicine.

United States: 351 vs. 361 Products

In the U.S., the FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) through two main pathways, named after sections of the Public Health Service Act:

• Section 361 products: Lower-risk products that are regulated solely as HCT/Ps. They are not subject to an FDA pre-approval process, though they must follow rules on donor screening, manufacturing practices, and infection control.
• Section 351 products: Products regulated as drugs, devices, and/or biological products. These require full FDA review, including clinical trials and formal approval, before marketing.

According to NIH regulatory guidance, a product is regulated under Section 351 if it does not meet all of the criteria for 361 status. The key criteria include whether the product:

1. Is minimally manipulated
2. Is intended for homologous use (performing the same basic function in the recipient as in the donor)
3. Does not depend on the metabolic activity of living cells for its primary function (with certain exceptions)

Genetically engineered therapies such as CAR-T fall clearly under Section 351. This distinction is also important for patients, since some clinics market minimally regulated products with claims that would normally require 351-level evidence.

European Union: Minimally Manipulated Cells vs. ATMPs

The EU framework distinguishes between minimally manipulated cells intended for homologous use and Advanced Therapy Medicinal Products (ATMPs). ATMPs are further divided into:

• Somatic cell therapy medicinal products: Cells that have been substantially manipulated or are used for a different function than their original one.
• Gene therapy medicinal products: Products that introduce, modify, or edit genetic material.
• Tissue-engineered products: Cells or tissues engineered to repair, regenerate, or replace human tissue.

Some products, such as CAR-T, sit at the intersection of cell and gene therapy, which is why regulators and industry reports sometimes count them in both categories.

The Oncology Adoptive-Cell Therapy Landscape in 2026

Oncology is the fastest-evolving and most clinically visible segment of cell therapy. Oncology represents 71.2% of the cell therapy market in 2026, and T cells hold a 74.9% market share, reflecting the dominance of T-cell-based cancer treatments. Adoptive cell therapy (ACT), which involves collecting, enhancing, or engineering immune cells and returning them to the patient, is the core concept tying these approaches together. For a snapshot of sector-wide momentum, see this Alliance for Regenerative Medicine 2026 data summary.

CAR-T Cell Therapy

CAR-T therapy engineers a patient’s T cells to express a chimeric antigen receptor (CAR) that recognizes a specific target on cancer cells. As of 2026, seven CAR-T therapies have been approved by the FDA, treating various forms of leukemia, lymphoma, and multiple myeloma.

Key characteristics of the approved CAR-T class:

• All approved products are autologous, manufactured from the patient’s own T cells.
• Targets are CD19 (for B-cell malignancies) or BCMA (for multiple myeloma).
• All approved indications are blood cancers.

Despite more than a decade of development, no allogeneic, off-the-shelf CAR-T therapy has yet received regulatory approval. Commercially, CAR-T has evolved from a last-resort treatment into a market exceeding $5 billion, with CARVYKTI growing at near-100% year-over-year rates and Yescarta maintaining market leadership.

The Shift Toward Allogeneic and In Vivo CAR-T

A paradigm shift is underway. Two emerging categories are reshaping the traditional autologous/allogeneic binary:

• Allogeneic CAR-T: Donor-derived, often gene-edited cells designed for off-the-shelf use.
• In vivo CAR-T: Instead of engineering cells outside the body, vectors deliver CAR constructs directly into a patient’s circulating T cells. This eliminates ex vivo cell processing. As one 2026 review describes it, the construct itself becomes an off-the-shelf genetic payload, while the effector remains the patient’s own immune system.

Major 2026 deal activity, including Eli Lilly’s acquisition of Orna Therapeutics for its circular-RNA in vivo CAR-T platform, underscores how seriously the industry is treating this new category.

CAR-NK Cell Therapy

CAR-NK therapy applies the CAR concept to natural killer cells. Interest is growing because NK cells have intrinsic cytotoxicity, carry a lower risk of graft-versus-host disease, and show strong potential for off-the-shelf allogeneic use, including emerging applications in natural killer cell therapy for solid tumors.

Tumor-Infiltrating Lymphocyte (TIL) Therapy

TIL therapy uses immune cells that naturally infiltrate a tumor. These cells are extracted from tumor tissue, expanded in large numbers, and reinfused. TILs exist in two biological subtypes:

• Intratumoral TILs (iTILs): Found within the tumor cell nests
• Stromal TILs (sTILs): Found in the surrounding supportive tissue

Lifileucel (AMTAGVI) is the first FDA-approved T-lymphocyte cellular therapy for solid tumors. It is indicated for metastatic melanoma and is under investigation for lung, head and neck, sarcoma, and cervical cancers.

Dendritic Cell Vaccines

Dendritic cell therapies train the immune system rather than directly attacking tumors. Sipuleucel-T (Provenge), an autologous dendritic cell-based vaccine approved in 2010 for metastatic castration-resistant prostate cancer, remains the only FDA-approved cancer vaccine of its kind.

Beyond Oncology: Other Clinically Established Cell Therapy Categories

A common misconception is that cell therapy equals CAR-T. In reality, the taxonomy extends well beyond cancer, including applications such as non-small cell lung cancer therapy.

Hematopoietic Stem Cell Transplantation (HSCT)

Bone marrow and stem cell transplants are among the oldest and most established cell therapies. They are used for blood cancers, immune disorders, and inherited blood diseases, and can be autologous or allogeneic.

Gene-Modified Autologous HSC Therapies: Sickle Cell Disease

Casgevy and Lyfgenia, both FDA-approved for sickle cell disease, are a concrete example of how classification lenses overlap. Each is:

• Autologous (the patient’s own stem cells, so no donor is needed)
• Stem cell-based (hematopoietic stem cells)
• Genetically modified before reinfusion

The difference lies in the technology: Casgevy uses CRISPR/Cas9 gene editing, while Lyfgenia uses a lentiviral vector. Before these approvals, a bone marrow transplant from a donor was the only curative option for sickle cell disease.

Mesenchymal Stromal Cell (MSC) Therapy

Remestemcel-L (Ryoncil), approved by the FDA in December 2024, is an allogeneic bone marrow-derived MSC therapy for steroid-refractory acute graft-versus-host disease in children. It is the first MSC product approved by the FDA for any indication.

Regenerative and Aesthetic Applications: Hair Restoration

Hair restoration is a popular area where cell therapy terminology frequently appears. Named sub-types include bone marrow-derived stem cell therapy, PRP combined with stem cells, exosome therapy, stem-cell-enhanced hair transplants, and scalp-derived cellular micrografting. These can be split into:

• Cell-based approaches: Autologous stem cell micrografts or follicle-derived cell suspensions
• Cell-free approaches: Secretome products, cytokines, and exosomes, which use cell-derived signals rather than living cells

Applying the regulatory lens is especially useful here, since many aesthetic offerings operate under minimal-manipulation frameworks rather than full drug approval. Prospective patients can also review candidacy considerations for stem cell baldness treatment before pursuing a procedure.

2026 Market Snapshot: Sizing the Cell Therapy Landscape

Market-size estimates for cell therapy in 2026 vary widely, ranging from roughly $9 billion to more than $19 billion depending on the research firm. This variance stems largely from definitions: some reports bundle CAR-T, MSC, and HSCT products together, while others separate them or count genetically modified cell therapies under gene therapy. Readers should interpret any single figure cautiously and check what it includes.

A few data points are more consistent across sources:

• T cells remain the dominant cell type, accounting for a 74.9% market share in 2026.
• Oncology remains the leading indication, representing 71.2% of the market in 2026.
• The pipeline is broad: According to the American Society of Gene & Cell Therapy’s Q1 2026 report, 2,132 gene therapies (including genetically modified cell therapies like CAR-T) and 881 non-genetically modified cell therapies are in development, from preclinical through pre-registration stages.

This pipeline breadth reflects the many categories covered in this map. It spans autologous and allogeneic products, stem and non-stem cells, unicellular and multicellular designs, and therapies regulated under every major framework.

How to Use This Classification Map

Different readers will find different lenses most useful.

• Patients and caregivers: Focus on origin (autologous vs. allogeneic) and the clinical category relevant to the condition in question, such as CAR-T, TIL, MSC, or HSCT. These details shape what treatment involves, including whether a donor is needed and how long manufacturing may take. Those researching options nearby may also want to explore regenerative medicine centers.
• Students and journalists: Use the academic framework (stem vs. non-stem, unicellular vs. multicellular) to build a structured understanding and to describe new therapies accurately.
• Biotech professionals and investors: Prioritize regulatory classification (351 vs. 361, ATMP subtypes) alongside market and pipeline data to inform due diligence and assess development risk. See also biotechnology examples for additional context on the wider sector.

In every case, this guide works best as a reference hub to consult before navigating to disease-specific or treatment-specific deep dives.

Conclusion: A Field Defined by Multiple, Overlapping Taxonomies

Cell therapy cannot be understood through a single classification axis. Origin, biological source, academic framework, and regulatory status each tell a different part of the story, and a single product often belongs to several categories at once. Casgevy, for example, is simultaneously autologous, stem cell-based, gene-modified, and regulated as a full biologic.

The taxonomy is also changing in real time. The shift from purely autologous models toward allogeneic and in vivo platforms is blurring the boundaries that have defined the field for years. Understanding these categories equips patients, students, and professionals to critically evaluate new developments as they emerge, and to separate rigorously regulated therapies from loosely defined marketing claims.

Explore Related Cell Therapy Topics

This classification map serves as the foundation for more focused content. Readers can continue their research through disease-specific and treatment-specific topics built on this taxonomy, including CAR-T deep dives, sickle cell gene therapy, and hair restoration cell therapy options.

Readers are encouraged to bookmark or share this guide as a reference whenever new cell therapy terminology appears in the news or in clinical conversations. Because the field evolves quickly, this taxonomy will continue to be updated to reflect new developments and emerging categories.